Nektar Therapeutics (NKTR) Tops Q2 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $60.98 +0.10%
EPS Growth %: +26.6%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +26.6%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $21.79 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Wall Street scrambles to lift Micron price targets ahead of earnings
- FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
